 CARLSBAD, Calif.--BUSINESS WIRE--- LCTX LineageCell--Lineage Cell Therapeutics, Inc. NYSE American and TASE: LCTX, a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that restoration of retinal tissue was observed in two additional patients enrolled in the Companys Phase 12a study of its lead product candidate, OpRegen. OpRegen is an allogeneic retinal pigment epithelium RPE cell transplant therapy in development for the treatment of age-rel 